

THE PRESENT AND FUTURE

STATE-OF-THE-ART REVIEW

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis



Sotirios Tsimikas, MD,^a Sergio Fazio, MD, PhD,^b Keith C. Ferdinand, MD,^c Henry N. Ginsberg, MD,^d Marlys L. Koschinsky, PhD,^e Santica M. Marcovina, PhD, ScD,^f Patrick M. Moriarty, MD,^g Daniel J. Rader, MD,^h Alan T. Remaley, MD, PhD,ⁱ Gissette Reyes-Soffer, MD,^d Raul D. Santos, MD, PhD,^j George Thanassoulis, MD,^k Joseph L. Witztum, MD,^l Simhan Danthi, PhD,ⁱ Michelle Olive, PhD,ⁱ Lijuan Liu, PhDⁱ

ABSTRACT

Pathophysiological, epidemiological, and genetic studies provide strong evidence that lipoprotein(a) [Lp(a)] is a causal mediator of cardiovascular disease (CVD) and calcific aortic valve disease (CAVD). Specific therapies to address Lp(a)-mediated CVD and CAVD are in clinical development. Due to knowledge gaps, the National Heart, Lung, and Blood Institute organized a working group that identified challenges in fully understanding the role of Lp(a) in CVD/CAVD. These included the lack of research funding, inadequate experimental models, lack of globally standardized Lp(a) assays, and inadequate understanding of the mechanisms underlying current drug therapies on Lp(a) levels. Specific recommendations were provided to facilitate basic, mechanistic, preclinical, and clinical research on Lp(a); foster collaborative research and resource sharing; leverage expertise of different groups and centers with complementary skills; and use existing National Heart, Lung, and Blood Institute resources. Concerted efforts to understand Lp(a) pathophysiology, together with diagnostic and therapeutic advances, are required to reduce Lp(a)-mediated risk of CVD and CAVD. (J Am Coll Cardiol 2018;71:177-92) © 2018 by the American College of Cardiology Foundation.

From the ^aVascular Medicine Program, Sulpizio Cardiovascular Center, Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, California; ^bOregon Health & Science University, Portland, Oregon; ^cTulane Medical Center, New Orleans, Louisiana; ^dCollege of Physicians and Surgeons, Columbia University, New York, New York; ^eRobarts Research Institute and Department of Physiology & Pharmacology Schulich School of Medicine & Dentistry, University of Western Ontario, London, Ontario, Canada; ^fDepartment of Medicine, University of Washington, Seattle, Washington; ^gUniversity of Kansas Medical Center, Kansas City, Missouri; ^hPerelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; ⁱNational Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland; ^jHeart Institute (InCor) University of Sao Paulo Medical School Hospital and Hospital Israelita Albert Einstein, Sao Paulo, Brazil; ^kMcGill University Health Center, Montreal, Quebec, Canada; and the ^lDivision of Endocrinology, Department of Medicine, University of California San Diego, La Jolla, California. The contents of this paper are solely the responsibility of the authors and do not necessarily reflect the official views of the National Heart, Lung, and Blood Institute (NHLBI), the National Institutes of Health (NIH), or the U.S. government. Dr. Tsimikas has received research support from the Fondation Leducq and NIH grants R01-HL119828, R01-HL078610, R01 HL106579, R01 HL128550, R01 HL136098, P01 HL136275 and R35 HL135737; currently has a dual appointment at the University of California San Diego and Ionis Pharmaceuticals; and is a coinventor and receives royalties from patents owned by the University of California San Diego on oxidation-specific antibodies. Dr. Fazio has served as an advisor/consultant for Merck, Kowa, Amarin, Amgen, Akcea, and Pfizer; and has received research support from NIH NHLBI grant R01HL132985. Dr. Ferdinand has served as a consultant for Amgen, Sanofi, Novartis, Quantum Genomics, and Boehringer Ingelheim. Dr. Ginsberg is supported by NIH 1R35HL135833; has received research support from Merck, Sanofi/Regeneron, Amgen, Ionis Pharmaceuticals, and Pfizer Cardiovascular Research; and has served as a consultant for Amgen, Ionis, and Sanofi/Regeneron. Dr. Koschinsky has served as a consultant for Ionis Pharmaceuticals, Sanofi, and Eli Lilly; and has received research support from the Canadian Institutes of Health Research (MOP# 126076), the Heart and Stroke Foundation of Ontario (G-13-0003091), the Natural Sciences and Engineering Research Council (RGPIN/5006-2015), the Pfizer ASPIRE Cardiovascular Grant, Ionis Pharmaceuticals, Regeneron Pharmaceuticals, Eli Lilly, and Pfizer.



Listen to this manuscript's
audio summary by
JACC Editor-in-Chief
Dr. Valentin Fuster.



**ABBREVIATIONS
AND ACRONYMS****apo** = apolipoprotein**CAVD** = calcific aortic valve disease**CD36** = cluster of differentiation 36 receptor**ICD-10** = International Classification of Diseases-10th Revision**Lp(a)** = lipoprotein(a)**LRP1** = low-density lipoprotein receptor-related protein 1**OxPL** = oxidized phospholipids**PCSK9** = proprotein convertase subtilisin kexin type 9**SNP** = single-nucleotide polymorphism**SR-BI** = scavenger receptor B-1

Lipoprotein(a) [Lp(a)] is composed of an apolipoprotein (apo) B-containing low-density lipoprotein (LDL)-like particle, covalently linked to the plasminogen-like glycoprotein apo(a) (1). Circulating plasma Lp(a) levels are primarily determined by the *LPA* gene locus encoding apo(a), with some influence from the *APOE* locus (2) and proprotein convertase subtilisin kexin type 9 (PCSK9) R46L loss of function mutations (3,4). *LPA* is highly polymorphic in size due to the number of kringle IV type 2 (KIV₂)-encoding sequences, giving origin to >40 apo(a) isoforms varying in distribution among individuals and populations.

Lp(a) is a highly prevalent genetic risk factor for cardiovascular disease (CVD) and calcific aortic valve disease (CAVD). Lp(a) levels in the atherothrombotic range are generally accepted as >30 to 50 mg/dl or >75 to 125 nmol/l (1,5). Such levels affect 20% to 30% of the global population (6,7), with possibly higher incidence in patients with established CVD (8) and CAVD (9). Importantly, >1 billion people globally have elevated levels of Lp(a). Convincing evidence has emerged from pathophysiological, epidemiological, and genetic studies on the causality of Lp(a) in contributing to CVD (myocardial infarction [MI], stroke, peripheral arterial disease, and heart failure) and CAVD (10-12).

Evidence from randomized statin and PCSK9 inhibitor trials, including 4S (Scandinavian Simvastatin Survival Study), AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes), JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), LIPID (Long-Term Intervention with

Pravastatin in Ischaemic Disease), and FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), have shown that when Lp(a) is elevated, the event rates are higher at any achieved LDL-C level, consistent with unaddressed Lp(a)-mediated risk. The Lp(a)-lowering effects of PCSK9 and CETP inhibitors, mipomersen, and antisense oligonucleotides have raised interest in Lp(a) from a mysterious particle of interest primarily to a small cadre of clinical lipidologists to the broader investigative, pharmaceutical, and cardiology communities.

Significant knowledge gaps exist in Lp(a) biology and pathophysiology. To address these gaps, the National Heart, Lung, and Blood Institute convened a Working Group on Future Research Directions on Lipoprotein(a) and Cardiovascular Disease. The working group (WG) brought together 14 experts from diverse backgrounds in Lp(a) basic, translational, and clinical sciences. In alignment with the Institute's Strategic Plan Goals 1, 2, and 3, the group focused on Lp(a) metabolism; pathophysiology, including appropriate animal models for Lp(a) research; Lp(a) measurements; current and emerging therapies for elevated Lp(a); identification of patients at high-risk for Lp(a)-mediated risk; understudied populations; and physician, patient, and public awareness of Lp(a) as a CVD and CAVD risk factor. The salient features of the discussion and recommendations are provided in the following text.

**Lp(a) NOMENCLATURE AND
CLINICAL DIAGNOSIS**

A standardized nomenclature for lipoprotein(a) is not currently available, and different names have been used for Lp(a) since its initial publication in 1963.

Dr. Marcovina has served as an advisor/consultant to Denka Seiken, MedTest, and Amgen. Dr. Moriarty has served as an advisor/consultant to Amgen, Regeneron, Sanofi, RegenXBio, Duke Clinical Research, Alexion, Esperion, Eliaz Therapeutics, and Ionis; has served on the speakers bureau for Amgen, Sanofi, and Regeneron; and has received research support from Regeneron, Sanofi, Amgen, Ionis, Catabasis, Pfizer, Novartis, Kaneka, Stage 2 Innovations, Zydus Discovery, Gemphire, Kowa, Akcea, FH Foundation, and Genzyme. Dr. Rader has served as a consultant for Novartis. Dr. Reyes-Soffer has served as an advisor/consultant for Merck; and has received research support from Merck, Sanofi/Regeneron, Ionis Pharmaceuticals, Pfizer Cardiovascular Research, and NIH grants UL1TR001873 and KL2TR001874. Dr. Santos has served as an advisor/consultant to Amgen, AstraZeneca, Biolog, Boehringer Ingelheim, Genzyme, Merck, Novo Nordisk, Pfizer, Eli Lilly, Kowa, Unilever, Sanofi/Regeneron, Torrent, and Procaps; has received research honoraria from Pfizer, Akcea, Amgen, and Sanofi; and has received speaker honoraria from Amgen, Biolog, Sanofi/Regeneron, and Merck. Dr. Thanassoulis has served as an advisor/consultant to Servier Canada, Amgen, and Ionis; has served on the speakers bureau of Servier Canada, Regeneron, and Sanofi; and has received research support from Ionis, Servier Canada, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada, and NIH grant R01 HL128550. Dr. Witztum has served as a consultant to Ionis Pharmaceuticals; is supported by NIH grants P01 HL088093, R01 HL119828, R35 HL135737, and P01 HL1136275; and is coinventor and receives royalties from patents owned by the University of California San Diego on oxidation-specific antibodies. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Except for the first author and National Heart, Lung, and Blood Institute (NHLBI) coauthors, the remaining coauthors are listed alphabetically.

The WG recommends calling this lipoprotein “lipoprotein(a)” or “Lp(a),” with no space between “lipoprotein” and “(a).” Furthermore, kringle numbers of apo(a) should be reported by Roman numerals, and kringle types subscripted (e.g., KIV₂ for kringle IV type 2). Subjects with elevated levels should be described as having “elevated Lp(a)” or “hyperlipoproteinemia(a).” Traditional thresholds for elevated Lp(a) are >30 mg/dl or >75 nmol/l, which approximate the 75th percentile in white populations and also reflect epidemiological data of CVD risk thresholds in primary care populations (6,13). In the United States, an ICD-10 code for the diagnosis of elevated Lp(a) levels does not exist. Clinicians have no way to document elevated Lp(a) levels, except with the use of a generic hypercholesterolemia code. The lack of an ICD-10 code also limits research on Lp(a) using electronic health records.

GUIDELINE RECOMMENDATIONS FOR MEASURING Lp(a)

The European Society of Cardiology/European Atherosclerosis Society have given a Class IIa, Level of Evidence: C recommendation for measuring Lp(a) in patients with premature CVD, familial hypercholesterolemia (FH), family history of premature CVD or family history of elevated Lp(a), recurrent CVD despite optimal lipid-lowering therapy, or a ≥5% 10-year risk of fatal CVD according to the SCORE algorithm (5). They also suggest that the risk of Lp(a) is significant when levels are >80th percentile, or >50 mg/dl (~100 to 125 nmol/l), for European populations. It is emphasized that this threshold is higher than the risk threshold in primary care populations of >20 to 30 mg/dl (6,13,14). The Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult had similar recommendations, but used a cutoff of Lp(a) >30 mg/dl to assign abnormal levels (15). The National Lipid Association also endorses measurement of Lp(a) in similar patient subsets (16).

WHAT ARE THE KNOWLEDGE GAPS IN THE Lp(a) FIELD?

Since the publication of Lp(a) in 1963, much has been learned about Lp(a). However, significant gaps in knowledge are present, as summarized in the following text. These gaps can be organized in several themes: defining metabolism; understanding pathophysiological mechanisms; standardizing measures of Lp(a); defining mechanisms through which current and emerging therapies affect Lp(a) levels; placing

effort to elucidate the role of Lp(a) in understudied, high-risk populations; and testing the Lp(a) hypothesis. For example, a physiological function of Lp(a) has not been determined; the sites where apo(a) and apoB are assembled to generate the Lp(a) particle, such as intrahepatocyte, space of Disse, or vascular lumen, remain controversial; the influence of genetic and epigenetic regulatory elements, as well as hormonal, inflammatory, comorbid, and dietary influences on *LPA* gene expression have not been comprehensively studied; the nature and extent of various clearance mechanisms, such as hepatic (LDLR, SR-B1, LRP-1, PLG) and nonhepatic receptors or renal mechanisms, are not well delineated; and Lp(a) is composed of ~30% to 45% cholesterol by mass, and this is reported as part of the “LDL-C” laboratory measurement (17). In the current era of very low LDL-C levels, the contribution of Lp(a) cholesterol to “LDL-C” may be substantial. The physiological and clinical implications of this fact are unknown; the composition/functional correlation between the Lp(a) lipidome and proteome with different Lp(a) levels and apo(a) isoform sizes is understudied.

Regarding pathophysiological mechanisms, Lp(a) may contribute to CVD and CAVD via its LDL-like component, pro-inflammatory effects of oxidized phospholipids (OxPL) on both apoB and apo(a) (18), and antifibrinolytic/prothrombotic effects of apo(a). The contribution of the strong lysine binding site in apo(a) as a mechanism to enhance Lp(a) accumulation in vascular tissues, interfere with plasminogen activation, and mediate the covalent binding of OxPL, and the in vivo roles and relative contributions of these mechanisms require further study. Because Lp(a) is not present in laboratory animals, appropriate experimental models have not been optimized to study its metabolism and mechanism of action in disease processes. The relationship and contribution of Lp(a) to valvular and vascular calcification and whether differences exist between Lp(a)-mediated processes in the arterial wall and aortic valve is not known, and preliminary data suggest a proinflammatory role for the OxPL of Lp(a) on monocytes. Whether a similar property applies to endothelial cells, macrophages, as well as B and T lymphocytes is not known; Lp(a) has shown acute phase properties in some studies, particularly in acute MI and rheumatological diseases, but this requires further study to assess the mechanisms, extent, and relevance of these effects.

For clinical risk prediction, Lp(a) is a risk factor for CVD in both primary and secondary prevention settings, but the risk of Lp(a) for recurrent CVD events in

settings of highly aggressive secondary prevention is not well understood; whether different Lp(a) risk thresholds exist for CVD versus CAVD remains to be established; and Lp(a) in high-risk populations, such as post-ACS, FH, chronic renal failure, diabetes, and the elderly, has not been well studied epidemiologically. Whether such patients would benefit from Lp(a) lowering is not known; the *in vivo* roles of Lp(a) in mediating both venous and arterial thrombosis have not been established. Studies of how modification of Lp(a) levels affects processes of thrombosis and fibrinolysis have not been reported. For clinical risk prediction, it is not known whether absolute thresholds (i.e., >30 mg/dl or >75 nmol/l), risk percentiles (i.e., >80%), or race-specific thresholds better identify high-risk individuals.

The mechanisms through which low-saturated-fat diets and statins potentially increase Lp(a) or how niacin, mipomersen, CETP, and PCSK9 inhibitors reduce Lp(a) levels are not fully established.

Finally, a randomized trial to test the Lp(a) hypothesis, namely that specifically reducing elevated Lp(a) levels leads to CVD or CAVD risk reduction, has not been carried out to date.

NHLBI WG: CHALLENGES AND RECOMMENDATIONS

The WG identified several important challenges and barriers that have inhibited the full understanding of the role of Lp(a) in CVD and CAVD. The main areas include the lack of significant public and private funding for basic Lp(a) research, the low number of applications, the low success rate of peer-reviewed applications, the lack of Lp(a) expertise in atherosclerosis/inflammation on grant peer-review panels, the lack of reliable *in vitro* cell lines and *in vivo* animal models, the lack of access to large biorepositories for biomarker and clinical research, and the lack of standardization of Lp(a) assays. Currently, there is also a very small cadre of active investigators in the area of Lp(a) biology. The reasons are multiple and complex, but likely reflect a combination of the lack of awareness, until recently, of investigators on the large global impact of Lp(a) in CVD and AS, the lack of mentoring programs to train Lp(a) investigators, the lack of available models to perform studies, and the lack of dedicated funding on Lp(a) focused research.

The WG broadly recommended the following.

- Explore mechanisms by which the NHLBI could facilitate basic, mechanistic, preclinical, and clinical research on Lp(a).
- Foster collaborative research and resource sharing; leverage expertise of different groups and centers with complementary skills, methods, and knowledge; and leverage existing resources, such as the NHLBI cohorts.
- Support assignment of an ICD-10 code for the diagnosis of elevated Lp(a). An ICD-10 code will enhance appropriate and specific diagnoses for patients at risk for Lp(a)-mediated disease, will identify Lp(a) as a potential etiological factor in patients with established CVD, and will allow assignment of familial or genetic risk, particularly in younger patients with CVD. Importantly, it will allow tracking of the prevalence of Lp(a) elevations in patient cohorts and the establishment of large databases for clinical research. Finally, with the emergence of novel Lp(a)-lowering therapies, appropriate diagnosis, prognosis, and potential assignment of therapeutic options will be needed for clinical care.
- Organize focused working groups comprised of wide array of stakeholders, including regulatory agencies, to standardize Lp(a) measurements.
- Educate the public, physicians, regulatory agencies, and funding agencies on the role of Lp(a) in CVD and CAVD.
- Develop evidence-based management plans for patients.

The **Central Illustration** summarizes the salient features of the unmet needs of Lp(a) pathophysiology.

To optimize research within the Lp(a) field, the WG identified 6 key areas of research priorities and corresponding recommendations listed and discussed in the following text.

SPECIFIC RESEARCH PRIORITIES AND RECOMMENDATIONS

PRIORITY #1: TO FULLY DEFINE MECHANISMS OF Lp(a) SYNTHESIS, ASSEMBLY, CLEARANCE, AND OTHER INFLUENCES ON CIRCULATING LEVELS.

There is uncertainty regarding the site(s) of the assembly of Lp(a), the role of secretion in determining plasma Lp(a) levels, the stability of the bond between apo(a) and apoB in plasma, and the mechanisms of clearance and degradation of Lp(a). Specifically, there is ongoing controversy about where apo(a) and apoB-100 bind to form Lp(a); which subtypes of apoB-100 lipoproteins bind to apo(a) to form Lp(a); whether the binding of apo(a) to apoB-100 is reversible, allowing apo(a) to bind to >1 apoB-100-containing lipoprotein during its lifespan in the circulation; and if Lp(a) or apo(a) leave the circulation via the LDLR pathway or through other potential pathways. Stable isotope

studies (19,20) have produced conflicting results, with early studies looking at the individual component proteins providing support for intracellular assembly of Lp(a), and more recent ones reporting extracellular assembly (20).



The mechanism(s) by which Lp(a) is catabolized remain remarkably poorly understood (20). Studies in preclinical model systems indicate that the liver is the major site of Lp(a) catabolism. Although many in vitro studies suggest that the LDLR can function as a clearance receptor for Lp(a), the available in vivo data are not entirely consistent with this: 1) humans with homozygous FH lacking the LDLR have similar rates of Lp(a) catabolism compared with control subjects; 2) LDLR knockout mice have similar rates of plasma Lp(a) turnover and hepatic uptake of Lp(a) compared with wild-type mice; and 3) statins up-regulate the LDLR leading to increased LDL catabolism but do not reduce Lp(a). The role of the LDLR in Lp(a) catabolism has been recently explored in vivo using stable isotopes to study of the effects of PCSK9 inhibition on apoB and Lp(a) metabolism. The results indicated that other receptors, in addition to the LDLR, must be involved in the clearance of Lp(a) from the circulation (19). Additionally, that study suggested that the LDLR only plays a significant role in Lp(a) clearance when hepatic levels of the receptor are very high and LDL levels are low, as is the case in PCSK9 inhibitor therapy. The continued uncertainty regarding the clearance of Lp(a) is exemplified by 2 recent in vitro studies with liver cells that provided completely conflicting results for the role of LDLR levels in Lp(a) uptake (21,22).

Studies have suggested a role for scavenger receptor class B type I (SR-BI), plasminogen receptors, low-density lipoprotein receptor-related protein 1 (LRP1), cluster of differentiation 36 receptor (CD36), and other receptors in liver-mediated Lp(a) uptake; this likely reflects the ability of both the LDL and apo(a) components to act as receptor ligands. For example, SR-BI mostly leads to the selective uptake of neutral lipids, such as cholesteryl esters from the Lp(a) core, but may not significantly alter the plasma clearance of apo(a) (23). The physiological relevance of these observations on the interaction of Lp(a) with SR-BI in humans is not clear, but patients with heterozygous loss of function mutations in SR-BI show increased plasma levels of Lp(a) (24). LRP1 may contribute to Lp(a) clearance via its affinity for apoB or Lp(a) and the different affinities for apoE isoforms. Competition of apoB-Lp(a) with apoE isoforms, particularly E4, which has strong affinity for LRP1, strongly influences Lp(a) levels (25). A member of the widely-expressed plasminogen receptor family,

PlgR_{KT}, was recently shown to mediate uptake of both Lp(a) and apo(a) in vitro (26). CD36 is a multiligand scavenger receptor that has been shown to bind and take up oxidized LDL and OxPL, which may potentially take up Lp(a) via its OxPL content (27).

Recommendations for research efforts for priority #1.

1. There is a need for studies that isolate “pure Lp(a)” that is not contaminated by LDL-apoB or high-density lipoprotein, to allow for the kinetic examination of the metabolism of the Lp(a)-apo(a) and Lp(a)-apoB components, as well as the influence of different apo(a) isoforms on metabolism. Emerging technologies based on quantitation by mass spectrometry of specific apo(a) and apoB peptides are a promising avenue. After validated methods of isolation are established, sophisticated modeling of the kinetic data will be crucial for investigators to address some of the key questions that remain, including whether: 1) apo(a) and apoB associate inside the liver; 2) apo(a) binds to apoB lipoproteins extracellularly in the bloodstream; and 3) there is recycling of Lp(a)-apo(a) or Lp(a)-apoB inside of the liver after uptake of the Lp(a) particle (19).
2. Along with methods to purify Lp(a), efforts should focus on annotating the particle’s lipidome and proteome in healthy subjects and patients with CVD and CAVD and determining the pathophysiological implications of these constituents.
3. Factors that influence apo(a) transcription should be systematically examined. Epigenetic modifications that mediate gene expression or pro-inflammatory signaling should also be studied (28).
4. The study of synthesis, assembly, and secretion of Lp(a) will require development of improved hepatocyte cell culture systems that express Lp(a) abundantly, because current human hepatocyte cell lines have very low apo(a) expression. Mouse primary hepatocytes need to have the proper regulatory elements of the entire *LPA* gene and not only complementary deoxyribonucleic acid constructs. Lp(a) transgenic monkey hepatocytes are not ideal for mechanistic studies because of significant differences in kringle type (e.g., some species lack KV), and all monkey Lp(a) lacks lysine binding affinity and OxPL content compared with human lines (29). The role of the LDLR in Lp(a) catabolism in the background of PCSK9 inhibition could be evaluated in vitro through systematic alterations of the ratios of LDLR, PCSK9, and Lp(a). Approaches to the study of Lp(a) catabolic pathways could include knock-downs of candidate receptors (LDLR, LRP1, CD36, SRB1, and PLG-R_{KT}) for measurement of their effect on Lp(a) uptake and degradation.

CENTRAL ILLUSTRATION Global Prevalence of Elevated Lp(a) Levels, Phenotypic Expression of Disease, and Metabolism of Lp(a)**Estimated World Population With Elevated Lp(a) > 50mg/dL = 1.43 Billion****Lp(a) Metabolism**

5. To complement candidate gene/receptor studies, unbiased genome-wide screens should be used to identify genes that when deleted reduce Lp(a) uptake and degradation. Modern molecular biology techniques, such as CRISPR/Cas9 libraries, are available to perform high-throughput, genome-wide screens on hepatocyte cell culture models and analyses for putative clearance receptors.
6. The mechanisms underlying the influence of apoE isoforms, which have very different affinities for the LDLR and LRP1 receptors that may influence Lp(a) binding, should be studied.
7. Once an understanding is obtained of the qualitative and quantitative role of various clearance mechanisms, studies will be required to identify the route of Lp(a) catabolism in both physiological and altered conditions. Naturally-occurring human “knockouts” of candidate genes could be used to study the effect on Lp(a) turnover in vivo. In concert, additional in vivo metabolic studies in humans should be performed in FH patients and subjects receiving PCSK9 inhibitors.
8. The recent introduction of antisense therapy has demonstrated an ability to lower plasma Lp(a) levels by up to 90% or more, even in subjects with greatly elevated Lp(a) levels (30,31). Although it is known that apo(a) messenger ribonucleic acid is reduced, it will be important to fully explore the kinetic mechanisms by which these reductions occur.

PRIORITY #2: TO UNDERSTAND THE MECHANISMS UNDERPINNING Lp(a) AND ITS ASSOCIATED OXIDIZED PHOSPHOLIPIDS IN MEDIATING RISK OF CVD AND AORTIC STENOSIS. The absence of Lp(a) in commonly used laboratory animals has resulted in limited options for the generation of relevant models to study Lp(a)-mediated mechanisms of atherogenesis and CAVD. Early studies used transgenic mice overexpressing a 17 kringle (17K)-containing human apo(a), which does not form a

covalent Lp(a) particle with mouse apoB-100. Subsequently, mice were generated overexpressing both human apo(a) and apoB-100, with resultant circulating covalent Lp(a) particles. There is conflicting evidence whether transgenic Lp(a) mice, which generally have levels of Lp(a) in normal range, are more susceptible to atherosclerosis than the transgenic human apoB-100 mice (32). Transgenic apo(a) rabbits expressing human 17K apo(a) formed circulating Lp(a) particles with endogenous rabbit apoB-100, also in normal range, with resulting lesions reminiscent of human atheromata (32).

A compelling hypothesis of the pro-inflammatory effects of Lp(a) is the preferential accumulation on Lp(a), compared with other lipoproteins, of phosphocholine-containing OxPL in lipid phase and covalently bound to apo(a). OxPL induce pro-inflammatory signaling in endothelial cells, smooth muscle cells, and macrophages and are pro-apoptotic when concentrations are high (27,33). They are relevant to the understanding of the pathobiology of Lp(a), as up to 85% to 90% of all OxPL found in human lipoproteins (at least those OxPL moieties detected by monoclonal antibody E06) are carried on Lp(a) (29). Further, clinical studies have demonstrated that the OxPL on Lp(a) mediates arterial wall inflammation and promotes monocyte inflammatory responses in humans (18). Finally, extensive epidemiological studies demonstrate that levels of OxPL on Lp(a) [measured as OxPL-apoB and OxPL-apo(a)] are robust predictors of CVD events and CAVD (1).

Recommendations for research efforts for priority #2.

1. The preferred Lp(a)-transgenic model should use physiologically-relevant apo(a) isoforms, along with the native regulatory elements, and human apoB-100 to generate transgenic mice. Plasma Lp(a) levels should be in the pathogenic range, at >30 mg/dl (>~75 nmol/l) and preferably >80th percentile of human populations (>50 mg/dl or >125 nmol/l). Human “apoB-100 only variant of apoB” should be used to maximize the extent Lp(a)

CENTRAL ILLUSTRATION Continued

The **top of the figure** depicts the migration of the *LPA* gene out of Africa to the rest of the world. Due to different migration patterns of people with different sized isoforms, as well as subsequent *LPA* gene remodeling, the worldwide prevalence of Lp(a) plasma levels is variable. The estimates of prevalence of elevated Lp(a) (>50 mg/dl or >125 nmol/l) are estimated based on current prevalence data, which are not necessarily entirely complete. The **bottom panels** depict the synthesis of 2 different sized apo(a) isoforms and the subsequent covalent binding to apo(a) to apoB-100 of an LDL-like particle and the assembly into Lp(a). Some Lp(a) particles can accumulate OxPL from cellular oxidative stress while others have no OxPL on them. The different sized Lp(a) are then secreted into the circulation and accumulate in vascular tissues and aortic valve leaflets over a lifetime. Lp(a) can further accumulate OxPL in the circulation from sites of active oxidation and inflammation. Lp(a) that does not accumulate in the vasculature or get taken up by peripheral cells can be further cleared by hepatic receptors, whose role and strength of association are not entirely known. A smaller portion of Lp(a) can be cleared by renal mechanisms or other unidentified pathways, ultimately reaching a plasma equilibrium of synthesis and clearance. Apo(a) = apolipoprotein a; ApoB = apolipoprotein B; ASGPR = asialoglycoprotein receptor; CD36 = cluster of differentiation 36 receptor; LDL = low-density lipoprotein; LDLR = low-density lipoprotein receptor; Lp(a) = lipoprotein(a); LRP1 = low-density lipoprotein receptor-related protein 1; OxPL = oxidized phospholipids; PlgR = plasminogen receptor; SRA = scavenger receptor type A; SRBI = scavenger receptor B-I.

- formation (34). Because OxPL are thought to bind specific amino acids at or near KIV₁₀, which contains lysine binding site, point mutations eliminating critical amino acids required for OxPL and lysine-binding should be engineered in the context of a physiological apo(a) isoform size (29).
2. OxPL is a general term that encompasses a large number of individual species. Fundamental knowledge of mechanisms by which OxPL on Lp(a), and specifically common individual OxPL moieties, affect cell signaling and function need to be defined. It is known that OxPL can mediate macrophage signaling via CD36, TLR2, TLR4, and/or combinations of these (35), but little is known of the detailed cellular or molecular biology that mediates these events in vivo. OxPL present as protein adducts, such as on apo(a) or apoB, may be biologically active also when present on microvesicles or on the surface of apoptotic cells and may mediate the pathogenicity of Lp(a) (36). In parallel, the development and standardization of techniques are needed to measure OxPL species on isolated Lp(a); plasma and tissues are critical for progress in this area of investigation. Mass spectrometry is used to measure OxPL species, but currently there are only a limited number of individual compounds available that can be used as standards to enable quantitative measurements. The NHLBI should facilitate development of a variety of OxPL analogues and standards by companies as was done during the LIPID MAPS program.
 3. A high priority is the development of murine models to allow for determination of role of OxPL in vivo in a variety of inflammatory settings and, in particular, in the context of atherosclerosis. Lp(a)-transgenic models might include models where the OxPL binding site is disabled, with concomitant expression of antibodies that specifically bind and neutralize OxPL, or with the passive transfer of such antibodies into mice with established disease. Studies of the effect on atherosclerosis/CAVD should be accompanied by mechanistic studies to examine the effect on expected changes in systemic and localized cellular inflammatory signaling, macrophage uptake of oxidized LDL/OxPL, and cholesterol accumulation.
 4. A number of murine models have been developed to study the pathogenesis of aortic stenosis, including use of the murine apoB-100 transgenic mice on the *Ldlr*^{-/-} background (37). Models with human apoB-100 can be used to determine the role of Lp(a) and OxPL as described in the previous text. Other models of CAVD, such as IGF-II

transgenic mice, and new ones when the pathogenesis of CAVD is further understood may also be considered in this context.

PRIORITY #3: TO DEVELOP A GLOBALLY STANDARDIZED MEASUREMENT OF Lp(a) APPLICABLE TO COMMERCIAL LABORATORIES AND TO DEFINE POPULATION RISK AMONG DIFFERENT ETHNIC/RACIAL GROUPS. The determination of Lp(a) levels in human samples are mainly performed by immunoassays using polyclonal antibodies against apo(a). Two types of approaches are presently used to express the levels of Lp(a). The first is based on the assignment of target values to the assay calibrators in terms of total Lp(a) mass [apo(a), apoB, and the lipid components]. The values are expressed in mg/dl, and there is no traceability of the various calibrators to any established reference material. The second approach, used in several commercial methods, is to assign the target values to assay calibrators traceable to the World Health Organization/International Federation of Clinical Chemistry and Laboratory Medicine secondary reference material PRM-2B (38). The values are expressed in nmol/l of apo(a), thus reflecting the number of circulating particles and not the variable mass of apo(a) or the lipid component. After method calibration, the values obtained in a set of individual samples are compared to those obtained by a monoclonal-antibody-based enzyme-linked immunosorbent assay method developed at the University of Washington that is considered the “gold standard” (39). Due to the size heterogeneity of apo(a), there is no conversion factor (despite an estimate of 2 to 2.5× conversion factor from mg/dl to nmol/l used in the published data) to transform the values from one unit to the other. An extensive review of the numerous issues affecting the measurement of Lp(a) has been published recently (40).

Before even attempting any standardization of Lp(a) measurements, as previously recommended (41), the assay calibration in mg/dl of total Lp(a) mass should be discontinued considering that only apo(a) is measured by the antibodies and that the mass of apo(a) is highly variable. In general, the first step for standardization of analytical methods is to calibrate the assays to be traceable to a common reference system. The second step is to verify harmonization of results obtained by the different methods after an accuracy-based common calibration is performed. However, this classic approach is rendered more complex by the inherent lack of accuracy of methods for measuring Lp(a) generated by the very large size polymorphism of apo(a). In fact, a major effort is needed by the manufacturers to render their method less affected by apo(a) size variations.

Due to its expertise in standardization of apoAI, apoB, and lipids, Lp(a) standardization activity has been performed in the past 15 years at the University of Washington by the Northwest Lipid Metabolism and Diabetes Research Laboratory in collaboration with some manufacturers by distributing the World Health Organization/International Federation of Clinical Chemistry and Laboratory Medicine reference material and by verifying values obtained by different methods. However, the PRM-2B reference material is close to being depleted, and a new material with high level of Lp(a) needs to be developed. To be internationally accepted by the scientific community, its value needs to be proven accurate and established by a nonantibody-based reference method. The Northwest Lipid Metabolism and Diabetes Research Laboratory has recently developed a Liquid Chromatography Select Reaction Monitoring Tandem Mass Spectrometry reference method accurately calibrated with a primary apo(a) reference preparation to be used to assign a target value to a secondary reference material.

However, the preparation of a secondary reference material and the numerous challenges that need to be overcome for the standardization/harmonization of Lp(a) methods, cannot be faced by a single laboratory. Everybody is in agreement that the availability of standardized methods that provide accurate and comparable results is considered essential for the performance of epidemiological studies, for future therapeutic clinical trials, and for determination of risk and therapy thresholds of Lp(a). However, there is no established definition of the approaches that need to be taken to achieve the goal of method standardization, and no consensus has been reached in the scientific community on how to cooperatively make decisions and implement the various standardization steps.

Along with standardized assay methodologies, the determination of what levels are considered abnormal is not fully determined. Data from subjects without prior CVD suggest the threshold for elevated CVD risk is >20 to 25 mg/dl or >50 to 75 nmol/l (13,14,42) but levels in subjects with prior CVD may be >40 to 50 mg/dl (1). Finally, in patients with or at risk for CAVD, levels may yet be even higher, at ~>40 to 60 mg/dl (9). Additional studies, particularly in the PCSK9 era of very low LDL-C, are needed to fully define risk thresholds for pre-existing CVD (43).

It is also well known that population means and median levels of Lp(a) vary by race/ethnicity. Most of the data of Lp(a) risk is derived from Caucasian populations, but recent efforts have also provided data in blacks and East and South Asians. A recent study in

blacks, whites, and Hispanics suggests that the circulating Lp(a) level predicts risk of major adverse cardiovascular events (MACE), irrespective of race/ethnicity, *LPA* single-nucleotide polymorphisms (SNPs) or isoforms (44,45).

Finally, it is well established that there are many *LPA* SNPs (estimate 40 to >200) that are associated with either low or high Lp(a). Interestingly, many of these SNPs are race specific or race prevalent, and the Lp(a) relationship of these SNPs is not necessarily in the same direction among races (45). For example, rs3798220 is of low prevalence (~3%) in Europeans and associated with high Lp(a), but high prevalence (>40%) in Hispanics and associated with low Lp(a) (45). This was due mainly to the concomitant presence of large isoforms in Hispanics, which are a stronger and direct driver of Lp(a) levels. It thus appears that these SNPs are tagging small isoforms and are not directly involved with Lp(a) production. Earlier data had also suggested that small apo(a) isoforms are associated with higher risk, and although this is true, when one adjusts for plasma Lp(a), this relationship is weak or absent (45,46).

Recommendations for research efforts for priority #3.

1. The support of the NHLBI to assist in the organization of a working group comprised of the relevant stakeholders, including scientific societies and regulatory agencies, to set standards for Lp(a) assay methodology is of paramount importance. The support of the Centers for Disease Control or other agencies to ensure the assays' accuracy and comparability as a nationwide effort will be very important for interpreting epidemiological studies, providing clinical care, and performing future therapeutic trials.
2. It is recommended that standardized Lp(a) assays report values in apo(a) particle number, as nmol/l. Mass assays should be phased out due to their inherent limitations. Along with this, significant educational efforts will be needed in the clinical community to understand what information the test gives and how it should be interpreted.
3. Defining scientifically-based risk and therapy thresholds in general populations, patients with pre-existing CVD or CAVD, and in different racial/ethnic groups of Lp(a) should be carried out with existing and future databases.
4. The public and physicians must be educated on recent guidelines on screening Lp(a) to identify high-risk patients.
5. Efforts to define the role of Lp(a) risk in various racial and ethnic groups should be promoted to normalize for baseline differences in population means and enhanced risk prediction.

6. *LPA* SNPs and isoforms should continue to be studied in a research realm to fully define their role as contributors to Lp(a)-mediated risk.

PRIORITY 4: TO UNDERSTAND THE MECHANISMS THROUGH WHICH THERAPEUTIC REGIMENS AFFECT Lp(a) LEVELS. The effects of therapeutic agents on circulating levels of Lp(a) are not well understood. For example, several studies have shown that both statins and low-saturated fat diets actually raise Lp(a) levels, a seeming paradox because both are associated with cardiovascular benefit (47). In contrast, most hormones, except growth hormone, lower Lp(a) levels. In contrast, niacin, mipomersen, PCSK9 and CETP inhibitors, and antibodies to interleukin-6 also decrease Lp(a) levels modestly. It is curious that all of these interventions have a modest effect on Lp(a), up to ~30% in either direction, suggesting modest regulatory influences on *LPA* gene expression, assembly, and/or clearance of Lp(a).

The FOURIER trial, with the power of 27,564 subjects, has shown a 27% reduction in Lp(a) levels with PCSK9 inhibition, which is one-half of that seen for LDL-C (59%) reduction, suggesting that LDLR up-regulation caused by PCSK9 inhibition also affects clearance of Lp(a). This is largely an unexpected phenomenon, because statins up-regulate the expression of the LDLR but have a neutral or Lp(a)-raising effect. The apparent paradox may be explained by the fact that PCSK9 inhibitors have a much larger effect on LDLR compared with the statins, and that Lp(a) is a poor competitor for LDLR binding in the presence of LDL. However, a recent study has suggested that the Lp(a) reduction caused by PCSK9 inhibition does not always parallel the reduction in LDL according to a 2:1 ratio, and a significant portion of treated subjects show discordance between a hefty LDL-C reduction and a minimal Lp(a) reduction (48). It is thus possible that apo(a) isoform length influences clearance behavior of Lp(a) in human plasma following up-regulation of LDLR. Finally, 40% of plasma PCSK9 compartmentalizes with LDL-sized apoB-containing lipoproteins, including LDL and Lp(a) (49,50), and the majority of lipoprotein-bound PCSK9 is in its intact form, not cleaved by furin. Because furin-cleaved PCSK9 is somewhat less effective on binding to LDLR compared with the intact PCSK9 form, it is possible that the balance between forms, as influenced by treatment with a PCSK9 inhibitor, also contributes to the degree of Lp(a) reduction on therapy.

Recommendations for research efforts for priority 4.

1. Baseline and follow-up absolute and mean percent change levels of Lp(a) should be measured and

reported routinely in clinical trials assessing lipid therapies to enhance the database of effects of therapeutic interventions.

2. It is now increasingly recognized that “LDL-C” is a misnomer, because no clinical assay can separate the cholesterol portion on Lp(a) [Lp(a)-C] from the measure of LDL-C, which is ~30% to 45% of Lp(a) mass in mg/dl. Thus, LDL-C is actually “LDL-cholesterol + Lp(a)-cholesterol” (17). In fact, all statin and PCSK9 outcomes studies have actually reported “LDL-C + Lp(a)-C” in relation to therapeutic effect. This is further supported by genome-wide association study data showing that the variation in LDL-C in response to statins is influenced by APOE and LPA loci. For example, carriers of SNPs associated with elevated Lp(a) have the smallest LDL-C reduction (51), findings also shown previously in JUPITER, ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial), and CARDS (Collaborative Atorvastatin Diabetes Study). Studies should consider teasing out the proportion of “LDL-C” that is true LDL-C versus Lp(a)-C. Initially this can be done by mathematical subtraction of Lp(a)-C from LDL-C, and the estimated LDL-C can be reported, as has been done in prior work (30,31). In the PCSK9 era of achieved very low LDL-C, a patient with elevated Lp(a) may have little to no circulating LDL-C and may also have circulating free apo(a). Such initial estimates are likely to have many limitations and should be complemented by rigorous biochemical studies to understand the relationship of Lp(a) mass to cholesterol, particularly in varying Lp(a) levels and isoforms. Such studies will also help to better understand the true LDL-C effects of LDL-C lowering agents.
3. Funding efforts should be focused on delineating the basic underlying mechanisms of diet, hormonal/post-menopausal status, statin therapy, mipomersen, and both PCSK9 and CETP inhibition on plasma Lp(a). This will not only provide insights into Lp(a) regulation, but will also help to understand the complex mechanisms of these treatments on Lp(a) biology. Understanding why low-fat diets and statins can raise Lp(a) in some patients will allow an assessment if this is part of the “residual risk” noted despite optimal and diet management.

PRIORITY 5: FOCUSED POPULATIONS AT RISK FOR CVD WITH HIGH Lp(a) REQUIRING SPECIAL RESEARCH EMPHASIS. Familial hypercholesterolemia. FH is associated with an elevated lifetime risk of CVD and higher Lp(a) levels increase this risk as shown in prospective studies (52). Lp(a) may also predispose to

aortic valve calcification in FH patients (53). There is controversy whether genetic defects that cause the FH phenotype, mainly defects on LDLR expression, increase Lp(a) levels.

Recommendations for research efforts for FH.

1. FH is the natural model to test the role of the LDLR on Lp(a) catabolism. Kinetic studies in both homozygous and heterozygous FH caused by the LDLR as well as other molecular defects in APOB or PCSK9 genes should be performed.
2. Cosegregation of molecular defects on the *LPA* gene that raise Lp(a) levels should be tested in individuals with proven FH-causing defects and in nonaffected relatives to test if effects on plasma Lp(a) are additive or synergistic.
3. Coronary computed tomography studies should also be performed to test if Lp(a) predisposes to coronary plaques in FH.
4. Lp(a) levels and genotypes should be tested in FH individuals prospectively to prove the association with CAVD in both homozygous and heterozygous FH.
5. Studies should examine whether more intensive LDL-C reduction with different treatments (PCSK9 inhibitors, lipoprotein apheresis) be instituted in FH individuals with higher Lp(a) levels.

Calcific aortic valve disease. CAVD remains the leading cause of aortic valve replacement in the developed world; yet, no drug therapies exist to slow disease progression. A genome-wide association study reported an association of *LPA* SNPs with computed tomographic (CT) assessment of aortic valve calcium (54), which has been validated in several other cohorts (55-57). In the ASTRONOMER (Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin) trial, elevated Lp(a) levels were linked to echocardiographically-measured progression, as well as the need for aortic valve replacement (AVR) (9). Finally, 4 studies have linked the role of OxPL and/or their downstream metabolites with a higher risk of developing CAVD (9,58-61). These studies are consistent with the hypothesis that Lp(a) may deliver OxPL to aortic valve leaflets, and that OxPL from Lp(a) and other sources (LDL, very low-density lipoprotein, apoptotic cells, and cell membrane lipids) can be converted to procalcifying lysophosphatidic acid by the enzyme autotaxin. These findings point to a potential novel therapeutic strategy to reduce CAVD by targeting Lp(a) and/or inactivating OxPL. It is estimated that 1 in 7 cases of aortic stenosis could be prevented by marked Lp(a) lowering (62).

Recommendations for research efforts for CAVD.

1. After development of appropriate Lp(a)-transgenic CAVD models as noted in the previous text, therapeutic studies to assess the effect of reduction in the progression rate can be conducted by Lp(a)-lowering agents, or by inactivating OxPL with antibodies directed to OxPL.
2. Clinical studies in CAVD, including valve surgery and transcatheter AVR, should evaluate the role of Lp(a) and OxPL biomarker studies in calcification with established techniques or with emerging techniques, such as Na¹⁸F positron emission tomographic imaging (63).
3. Although limited options currently exist to lower Lp(a), recent novel therapies such as antisense oligonucleotides to apo(a), which lower Lp(a) >90%, could be used in randomized trials to assess the effects on progression of CAVD (1,31). Several key questions remain to be addressed, including which stage of disease should be targeted (sclerosis, mild, moderate, or severe aortic stenosis); what Lp(a) threshold should be used (e.g., >50 mg/dl or >125 nmol/l); which agents and targets [Lp(a), OxPL, calcium] should be addressed; what outcomes should be monitored (subclinical outcomes such as aortic valve calcium, Na¹⁸F, valve velocity, or gradients vs. clinical outcomes such as valve replacement and death, or a combination). Typical endpoints in CVD outcomes trials, such as cardiovascular death and MI, will be low frequency in CAVD trials where the disease is known for many years and where death can be prevented by AVR; thus, they will not be useful as primary endpoints. Because the progression rate of CAVD on echocardiography measured by aortic valve velocity is a high-fidelity reflector of clinical complications, this may be the optimal primary endpoint in trials, with AVR as a secondary endpoint depending on the stage of the disease at entry into the trial.

Renal disease. It is known that Lp(a) levels are substantially increased in persons with end-stage renal disease (ESRD). Lp(a) catabolism is markedly impaired in patients with ESRD who are on dialysis. Lp(a) levels do not change with the initiation of dialysis, but do decrease upon renal transplantation. More recent evidence indicates that Lp(a) levels are elevated in chronic kidney disease (CKD) and increase with worsening of renal function over time. The mechanisms by which CKD and ESRD increase Lp(a) levels and impair Lp(a) catabolism are not understood. A key question has been whether elevated Lp(a) levels contribute to the increased cardiovascular risk in CKD. Recent data

indicate that Lp(a) is an independent predictor of incident CHD events and mortality in CKD (64). Thus, reducing Lp(a) in patients with CKD could be an important approach to reducing CV risk in this population.

Recommendations for research efforts for renal disease.

1. The mechanisms by which Lp(a) is elevated in CKD requires intense investigation and could provide insights into the normal pathways regulating Lp(a) metabolism.
2. The CKD population could be a valuable group for testing the effect of Lp(a)-lowering interventions on CV outcomes.

High thrombosis risk. Since the similarity between the apo(a) component of Lp(a) and the fibrinolytic proenzyme plasminogen was reported in 1987, a role for Lp(a) in thrombotic and fibrinolytic events in the vasculature has been a research focus (10). Mechanisms supporting an effect of Lp(a) in both promotion of clot formation and inhibition of fibrinolysis have been identified using in vitro systems and animal models. However, large Mendelian randomization studies have failed to demonstrate a role for elevated Lp(a) levels in venous thrombosis (65). The role of Lp(a) in arterial thrombosis is not fully defined, particularly because it is difficult to separate atherosclerosis from thrombosis clinically.

Recommendations for research efforts for high thrombosis risk.

1. Direct assessment of a role of Lp(a) in fibrinolysis/thrombosis can be accomplished using fat-fed transgenic Lp(a) mice. Thrombosis can be triggered by a variety of techniques, including chemical or mechanical irritants.
2. The role of Lp(a) in ongoing or past imaging studies, particularly plaque-specific techniques such as intravascular ultrasound, near-infrared spectroscopy, optical coherence tomography, or fluorodeoxyglucose-positron emission tomography, where blood samples are available should be analyzed to assess if Lp(a) is preferentially associated with plaque burden or features of plaque instability (thin fibrous cap, lipid pool, cholesteryl ester and macrophage content, and necrotic core), or both.
3. Gene-gene interactions between the *LPA* locus and thrombophilia susceptibility genes such as Factor V Leiden should be examined. This may be of particular importance in the pediatric population, where Lp(a) has been reported to be a risk factor for recurrent stroke in the absence of atherosclerosis (66).

Patients who have recurrent CVD events, progressive CAD, or refractory angina. Lipoprotein apheresis (LA) is increasingly being applied in patients with elevated Lp(a) and ongoing CVD, irrespective of LDL-C levels. In the United States, very few patients ($n < 50$) with ongoing CVD and isolated increased Lp(a) are currently receiving LA therapy, whereas in Germany there are >1,500 such patients. Three prospective/retrospective trials from Germany demonstrated reduction of CVD events by ~80% (pre-apheresis range: 0.41 to 2.80 MACE/year; post-apheresis range: 0.08 to 0.14 MACE/year) with LA therapy in CVD patients with Lp(a) >60 mg/dl and LDL-C ~100 mg/dl on maximally tolerated therapy (reviewed in Moriarty and Hemphill [67]). Recently, in patients with refractory angina and elevated Lp(a) >60 mg/dl, LA therapy was shown to improve coronary blood flow by cardiac magnetic resonance imaging and to reduce the frequency of angina (68). A second study showed that the best response of gene therapy with an AdVEGF-D (adenoviruses expressing human vascular endothelial growth factor-D) vector in patients with refractory angina was in the highest Lp(a) tertile at baseline (69).

Recommendations for research efforts for lipoprotein apheresis.

1. The mechanisms through which LA for elevated Lp(a) improves clinical benefit are not well defined. Comparing LA, which affects multiple lipid and viscosity and other parameters and lowers levels of PCSK9, to Lp(a)-lowering therapies that only affect Lp(a) levels may be informative. These studies can be complemented by biomarker studies that assess endothelial integrity, oxidation, inflammation, and viscosity, as well as changes in OxPL and monocyte pro-inflammatory activity, which can then be linked to clinical findings such as refractory angina and MACE.
2. Prospective, randomized trials in patients eligible for LA according to established criteria (controlled LDL-C, recurrent events or progression of CVD, Lp(a) >60 mg/dl) with elevated Lp(a) should be supported. A creative trial in that regard is now ongoing in Germany and Europe (MultiSELECT [Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes]; NCT02791802). Despite approval by the American Society for Apheresis and the International Society for Apheresis, LA apheresis is approved only in Germany for such patients, and it is felt to be unethical to perform such a trial in Germany. Thus, the German sites will all be randomized to apheresis and the non-German sites to "usual care." The

study has an estimated enrollment of 1,000 patients and is powered to assess a MACE endpoint. In the United States, where LA apheresis for such patients is exceedingly rare, is only performed ad hoc, and is not FDA approved, there are no impediments to a randomized clinical apheresis trial.

3. Ongoing studies of refractory angina should consider measuring Lp(a) in their cohorts to assess its relationship to both baseline symptoms and treatment effects. Consideration should also be given to stratify inclusion criteria based on baseline Lp(a) to ensure balanced baseline characteristics and allow an improved statistical assessment of any benefit.

Cerebrovascular accident in children and young adults.

The etiology of pediatric acute ischemic stroke (AIS) is complex, but evidence suggests that elevated Lp(a) may play a role (70). It is not clear if Lp(a) is a primary determinant, is part of a double-hit with other risk factors, or only plays a role in the extension of thrombus versus initiation of thrombus. Pediatric AIS is rare, but when it occurs, almost 40% is diagnosed as cryptogenic. For adults, most strokes are associated with atherosclerosis compared with only 2% in pediatric patients. Children with an elevated Lp(a) level have a 4-fold increased risk of AIS, and the risk of recurrent ischemic strokes is increased by more than 10× in patients with an elevated Lp(a) >90th percentile (66). These studies are limited by a lack of prospective methodology and are hypothesis generating at present.

Recommendations for research efforts for cerebrovascular accident.

1. Epidemiological studies on the role of Lp(a) in pediatric stroke should be supported to define incidence and prevalence of elevated Lp(a).
2. The association of Lp(a) with antifibrinolytic effects may be most evident in this population, as they generally do not have atherosclerosis, and should therefore be a focus of investigation.
3. Interactions between Lp(a) and other prothrombotic risk factors may be a useful avenue of research to tease out if Lp(a) has a primary, additive, or synergistic role in pediatric AIS.
4. Dedicated research studies to acutely lower Lp(a) in pediatric AIS, with apheresis or novel technologies, would be reasonable in assessing diminished risk of recurrence.

PRIORITY 6: TESTING OF THE “Lp(a) HYPOTHESIS”. The Lp(a) hypothesis, namely the randomization of patients with elevated Lp(a) levels to Lp(a)-lowering agents versus placebo in the setting of otherwise

guideline-recommended preventative therapies, has not been tested to date due to lack of therapeutic agents that specifically lower Lp(a). Although Mendelian randomization and genome-wide data provide strong evidence of causality, definitive proof will likely require an outcomes trial prior to clinical approval of any targeted drug therapy. The arrival of potent and specific therapies to lower Lp(a), such as antisense therapy (30,31), convey the beginning of the era of testing of the Lp(a) hypothesis.

The testing of the Lp(a) hypothesis in primary care populations is strongly supported by the putative causality derived from epidemiological and genetic studies. A cardiovascular outcomes trial in subjects with elevated Lp(a) but without prior CVD can be daunting in terms of power, size, cost, and duration of follow-up. However, the Lp(a) threshold in such patients where benefit may accrue is fairly low (i.e., >30 mg/dl) so that both ease of recruitment and efficacy would be favorable. The Lp(a) hypothesis can also be tested in secondary prevention cohorts, that is, in patients with prior CAD/MI, TIA/stroke, and PAD on maximally tolerated lipid therapies. In such patients, who are at higher risk and also accrue higher rates of recurrent events but are also on multiple prevention therapies for all risk factors, the strength of the association is less established in settings where LDL-C is <70 mg/dl (43,71). For example, in secondary prevention settings in randomized trials, LIPID, AIM-HIGH, and JUPITER (1), 4S (72), and TNT (73), showed that baseline and/or on-treatment Lp(a) predicts higher events rates even in settings with achieved LDL-C as low as 55 mg/dl. However, the epidemiological cohorts LURIC/GENIUS-CHD showed a higher association of elevated Lp(a) and CAD for the initial event but not subsequent mortality. The dal-Outcomes trial of CETP inhibition in a post-ACS setting, where Lp(a) can act as an acute phase reactant and potentially confound associations, showed no relationship to subsequent events (74). The SATURN IVUS trial showed no relationship of Lp(a) to atheroma progression (75); however, because Lp(a) is both an atherogenic and thrombotic risk factor and is most strongly associated with clinical MI, changes in atheroma volume may not fully reflect Lp(a) risk. A major disadvantage of all such studies is that subjects were not recruited for elevated Lp(a) and baseline levels are in the normal range (10 to 15 mg/dl); thus, they uniformly lack adequate power for hypothesis-testing hypotheses.

We propose that existing and new clinical CVD outcomes studies and trials measure Lp(a) and report their Lp(a)-related outcomes. Importantly, collaborative, patient-level meta-analysis should be

performed to define the role of baseline and on-treatment Lp(a) and CVD risk in secondary prevention settings. Additionally, reporting of high-risk patient subgroups (patients with recurrent events; younger patients with generically driven disease; and patients with FH, multiple revascularizations, or diabetes) and using a variety of Lp(a) cutoffs, such as >30, >50 to 60, and >100 mg/dl, may allow identification of patients who are most likely to benefit from Lp(a) lowering.

Finally, the Lp(a) hypothesis should ideally be tested in patients with optimal LDL-C reduction, but not necessarily based on an LDL-C goal, because many high-risk patients cannot achieve the target LDL-C (such as those with FH, with polygenic hypercholesterolemia, or who are statin intolerant). It is also crucial to emphasize that because the Lp(a)-C content is present in the laboratory measurement of “LDL-C” (17) and statins and ezetimibe tend to increase Lp(a) mass and Lp(a)-C levels (76), patients with elevated Lp(a) are less likely to achieve target LDL-C. This was recently suggested in the FOURIER trial (77), where in quartile 1 of achieved LDL-C (<0.5 mmol/l or ~20 mg/dl), the mean level of Lp(a) was 22 nmol/l (interquartile range: 9 to 53 nmol/l). In contrast, in quartile 5 (>2.6 mmol/l or ~100 mg/dl) the mean Lp(a) was 49 nmol/l (interquartile range: 9 to 188 nmol/l), further suggesting that the patients who achieve very low LDL-C are primarily the

patients with low Lp(a). Thus, using a low LDL-C cutoff in such a trial will inadvertently exclude many patients with elevated Lp(a) who are in the highest risk spectrum.

CONCLUSIONS

To improve public health in subjects with elevated Lp(a), all stakeholders need to be incentivized to work together to achieve these goals. The newly formed Lp(a) Foundation provides awareness and educational materials. A greater knowledge of Lp(a) biology will likely bring forward new insights that will enhance diagnostic and therapeutic options in patients at risk for Lp(a)-mediated vascular and valvular disease.

ACKNOWLEDGMENTS The authors thank Sandra Revell Tremulis for helpful discussions during the National Heart, Lung, and Blood Institute Working Group meeting entitled, “Future Research Directions on Lipoprotein(a) and Cardiovascular Disease,” held on March 20 to 21, 2017, in Bethesda, Maryland.

ADDRESS FOR CORRESPONDENCE: Dr. Sotirios Tsimikas, Vascular Medicine Program, Sulpizio Cardiovascular Center, University of California San Diego, 9500 Gilman Drive, BSB 1080, La Jolla, California 92093-0682. E-mail: stsimikas@ucsd.edu.

REFERENCES

1. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. *J Am Coll Cardiol* 2017;69:692–711.
2. Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S. Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients. *Arterioscler Thromb Vasc Biol* 2017;37:580–8.
3. Langsted A, Nordestgaard BG, Benn M, Tybjaerg-Hansen A, Kamstrup PR. PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis. *J Clin Endocrinol Metab* 2016;101:3281–7.
4. Verbeeke R, Boyer M, Boekholdt SM, et al. Carriers of the PCSK9 R46L variant are characterized by an antiatherogenic lipoprotein profile assessed by nuclear magnetic resonance spectroscopy—brief report. *Arterioscler Thromb Vasc Biol* 2017;37:43–8.
5. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. *Eur Heart J* 2016;37:2999–3058.
6. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J* 2010;31:2844–53.
7. Varvel S, McConnell JP, Tsimikas S. Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States. *Arterioscler Thromb Vasc Biol* 2016;36:2239–45.
8. Afshar M, Pilote L, Dufresne L, Engert JC, Thanassoulis G. Lipoprotein(a) interactions with low-density lipoprotein cholesterol and other cardiovascular risk factors in premature acute coronary syndrome (ACS). *J Am Heart Assoc* 2016;5:e003012.
9. Capoulade R, Chan KL, Yeang C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. *J Am Coll Cardiol* 2015;66:1236–46.
10. Boffa MB, Koschinsky ML. Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? *J Lipid Res* 2016;57:745–57.
11. Schmidt K, Noureen A, Kronenberg F, Utermann G. Structure, function, and genetics of lipoprotein (a). *J Lipid Res* 2016;57:1339–59.
12. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. *J Lipid Res* 2016;57:1953–75.
13. Erqou S, Kaptoge S, Perry PL, et al., for the Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA* 2009;302:412–23.
14. Khera AV, Everett BM, Caulfield MP, et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *Circulation* 2014;129:635–42.
15. Anderson TJ, Grégoire J, Pearson GJ, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. *Can J Cardiol* 2016;32:1263–82.
16. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. *J Clin Lipidol* 2011;5:338–67.
17. Yeang C, Witztum JL, Tsimikas S. ‘LDL-C’ = LDL-C + Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. *Curr Opin Lipidol* 2015;26:169–78.
18. van der Valk FM, Bekkering S, Kroon J, et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory

- monocyte response in humans. *Circulation* 2016;134:611-24.
19. Reyes-Soffer G, Pavlyha M, Ngai C, et al. Effects of PCSK9 Inhibition with alirocumab on lipoprotein metabolism in healthy humans. *Circulation* 2017;135:352-62.
20. Reyes-Soffer G, Ginsberg HN, Ramakrishnan R. The metabolism of lipoprotein (a): an ever-evolving story. *J Lipid Res* 2017;58:1756-64.
21. Villard EF, Thedrez A, Blankenstein J, et al. PCSK9 modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo. *J Am Coll Cardiol Basic Trans Science* 2016;1:419-27.
22. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML. Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. *J Biol Chem* 2015;290:11649-62.
23. Yang X-P, Amar MJ, Vaisman B, et al. Scavenger receptor-BI is a receptor for lipoprotein(a). *J Lipid Res* 2013;54:2450-7.
24. Yang X, Sethi A, Yanek LR, et al. SCARB1 gene variants are associated with the phenotype of combined high high-density lipoprotein cholesterol and high lipoprotein (a). *Circ Cardiovasc Genet* 2016;9:408-18.
25. Yeang C, Gordts PL, Tsimikas S. Novel lipoprotein(a) catabolism pathway via apolipoprotein(a) recycling: adding the plasminogen receptor PlgRKT to the list. *Circ Res* 2017;120:1050-2.
26. Sharma M, Redpath GM, Williams MJ, McCormick SP. Recycling of apolipoprotein(a) after PlgRKT-mediated endocytosis of lipoprotein(a). *Circ Res* 2017;120:1091-102.
27. Berliner JA, Leitinger N, Tsimikas S. The role of oxidized phospholipids in atherosclerosis. *J Lipid Res* 2009;50 Suppl:S207-12.
28. Hoeksema MA, Gijbels MJ, Van den Bossche J, et al. Targeting macrophage histone deacetylase 3 stabilizes atherosclerotic lesions. *EMBO Mol Med* 2014;6:1124-32.
29. Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein(a) and lipoprotein(a). *J Lipid Res* 2013;54:2815-30.
30. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. *Lancet* 2015;386:1472-83.
31. Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. *Lancet* 2016;388:2239-53.
32. Yeang C, Cotter B, Tsimikas S. Experimental animal models evaluating the causal role of lipoprotein(a) in atherosclerosis and aortic stenosis. *Cardiovasc Drugs Ther* 2016;30:75-85.
33. Boullier A, Friedman P, Harkewicz R, et al. Phosphocholine as a pattern recognition ligand for CD36. *J Lipid Res* 2005;46:969-76.
34. Schneider M, Witztum JL, Young SG, et al. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. *J Lipid Res* 2005;46:769-78.
35. Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. *Cell Metab* 2010;12:467-82.
36. Tsiatoulas D, Perkmann T, Afonyushkin T, et al. Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies. *J Lipid Res* 2015;56:440-8.
37. Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. *Circ Res* 2011;108:1392-412.
38. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). *Clin Chem* 2000;46:1956-67.
39. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). *Clin Chem* 1995;41:246-55.
40. Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. *J Lipid Res* 2016;57:526-37.
41. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions. *Clin Chem* 2003;49:1785-96.
42. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. *JAMA* 2009;301:2331-9.
43. Ray KK, Ginsberg HN, Davidson MH, et al. Modest potential association between reductions in lipoprotein(a) and major adverse cardiovascular events in the phase 3 trials of alirocumab versus control (abstr). *Circulation* 2016;134:A18484.
44. Virani SS, Brautbar A, Davis BC, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in Black and White subjects: The Atherosclerosis Risk in Communities (ARIC) Study. *Circulation* 2012;125:241-9.
45. Lee SR, Prasad A, Choi YS, et al. The LPA gene, ethnicity, and cardiovascular events. *Circulation* 2016;135:251-63.
46. Willeit P, Kiechl S, Kronenberg F, et al. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. *J Am Coll Cardiol* 2014;64:851-60.
47. Yeang C, Hung MY, Byun YS, et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). *J Clin Lipidol* 2016;10:594-603.
48. Edmiston JB, Brooks N, Tavori H, et al. Discordant response of low-density lipoprotein cholesterol and lipoprotein(a) levels to monoclonal antibodies targeting proprotein convertase subtilisin/kexin type 9. *J Clin Lipidol* 2017;11:667-73.
49. Tavori H, Giunzioni I, Linton MF, Fazio S. Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. *Circ Res* 2013;113:1290-5.
50. Tavori H, Christian D, Minnier J, et al. PCSK9 association with lipoprotein(a). *Circ Res* 2016;119:29-35.
51. Postmus I, Trompet S, Deshmukh HA, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. *Nat Commun* 2014;5:5068.
52. Santos RD, Gidding SS, Hegele RA, et al. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. *Lancet Diabetes Endocrinol* 2016;4:850-61.
53. Vongpromek R, Bos S, Ten Kate GJ, et al. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. *J Intern Med* 2015;278:166-73.
54. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. *N Engl J Med* 2013;368:503-12.
55. Arsenault BJ, Boekholdt SM, Dube MP, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective mendelian randomization study and replication in a case-control cohort. *Circ Cardiovasc Genet* 2014;7:304-10.
56. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. *J Am Coll Cardiol* 2014;63:470-7.
57. Cairns BJ, Coffey S, Travis RC, et al. A replicated, genome-wide significant association of aortic stenosis with a genetic variant for lipoprotein(a): meta-analysis of published and novel data. *Circulation* 2017;135:1181-3.
58. Bouchareb R, Mahmut A, Nsaibia MJ, et al. Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. *Circulation* 2015;132:677-90.
59. Nsaibia MJ, Mahmut A, Boulanger MC, et al. Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease. *J Intern Med* 2016;280:509-17.
60. Torzewski M, Ravandi A, Yeang C, et al. Lipoprotein(a)-associated molecules are prominent components in plasma and valve leaflets in calcific aortic valve stenosis. *J Am Coll Cardiol Basic Trans Science* 2017;2:229-40.
61. Kamstrup PR, Hung MY, Witztum JL, Tsimikas S, Nordestgaard BG. Oxidized phospholipids and risk of calcific aortic valve disease: The Copenhagen General Population Study. *Arterioscler Thromb Vasc Biol* 2017;37:1570-8.
62. Afshar M, Kamstrup PR, Williams K, Sniderman AD, Nordestgaard BG, Thanassoulis G. Estimating the population impact of lp(a) lowering on the incidence of myocardial infarction and aortic stenosis-brief report. *Arterioscler Thromb Vasc Biol* 2016;36:2421-3.

63. Jenkins WS, Vesey AT, Shah AS, et al. Valvular (18)F-Fluoride and (18)F-fluorodeoxyglucose uptake predict disease progression and clinical outcome in patients with aortic stenosis. *J Am Coll Cardiol* 2015;66:1200–1.
64. Bajaj A, Damrauer SM, Anderson AH, et al. Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC Study (Chronic Renal Insufficiency Cohort). *Arterioscler Thromb Vasc Biol* 2017;37:1971–8.
65. Emdin CA, Khera AV, Natarajan P, et al. Phenotypic characterization of genetically lowered human lipoprotein(a) levels. *J Am Coll Cardiol* 2016;68:2761–72.
66. Goldenberg NA, Bernard TJ, Hillhouse J, et al. Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. *Haematologica* 2013;98:802–7.
67. Moriarty PM, Hemphill L. Lipoprotein apheresis. *Endocrinol Metab Clin North Am* 2016;45:39–54.
68. Khan TZ, Hsu LY, Arai AE, et al. Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial. *Eur Heart J* 2017;38:1561–9.
69. Hartikainen J, Hassinen I, Hedman A, et al. Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. *Eur Heart J* 2017;38:2547–55.
70. McNeal CJ. Lipoprotein(a): its relevance to the pediatric population. *J Clin Lipidol* 2015;9:S57–66.
71. O'Donoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. *J Am Coll Cardiol* 2014;63:520–7.
72. Berg K, Dahlen G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. *Clin Genet* 1997;52:254–61.
73. Arsenault BJ, Barter P, DeMicco DA, et al. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. *PLoS One* 2014;9:e114519.
74. Schwartz GG, Ballantyne CM, Barter PJ, et al. Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-Outcomes randomized clinical trial. *JAMA Cardiol* 2017 Oct 25 [E-pub ahead of print].
75. Puri R, Ballantyne CM, Hoogeveen RC, et al. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: insights from SATURN. *Atherosclerosis* 2017;263:137–44.
76. Yeang C, Wilkinson MJ, Tsimikas S. Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. *Curr Opin Cardiol* 2016;31:440–50.
77. Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. *Lancet* 2017;390:1962–71.

KEY WORDS aortic stenosis, cardiovascular disease, lipoprotein(a), metabolism, pathophysiology, therapy